How Gottschalk was paid
$2.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Other | Total |
|---|---|---|---|---|---|
| Adrian GottschalkPresident and Chief Executive Officer | $638,000 | $1,334,037 | $385,990 | $3,000 | $2,361,027 |
| Steven BellonChief Science Officer | $505,000 | $469,255 | $222,200 | $3,000 | $1,199,455 |
| Alfonso Quintás-CardamaChief Medical Officer | $494,000 | $419,605 | $217,360 | $3,000 | $1,133,965 |
What changed and why
- $638K$638,000 CEO salary increased from $601,500 in 2024.
- $1.3M$1,334,037 CEO option awards nearly doubled from $673,861 in 2024.
- 110%110% of target bonuses were earned based on corporate performance goals.
- 55%55% was the CEO’s 2025 target bonus as a percentage of base salary.
- 2025 performance goals covered financing, clinical development, pipeline advancement, and research and development.
- $698KThe CEO’s 2026 base salary increased to $698,000.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.